2 documents

On Dec. 17, 2012, Abbott launched the Architect 2nd Generation Testosterone Assay in the U.S. for the quantitative determination of testosterone in human serum and plasma. The chemiluminescent microparticle immunoassay runs on Abbott's Architect analyzers....

Abbott said it received CE Mark approval for the Architect 2nd Generation Testosterone Assay to quantitatively determine testosterone levels in human serum and plasma with improved sensitivity, including in patients with low levels of circulating...